A Multi-Center, Factorial Study to Evaluate the Efficacy and Safety of 8-Week Treatment With VAA489 [Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined] and Alone in Essential Hypertensive Patients - Double-Blind Study of VAA489 in Patients With Essential Hypertension (Factorial Study).
Phase of Trial: Phase II/III
Latest Information Update: 31 May 2016
At a glance
- Drugs Amlodipine; Amlodipine/valsartan; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 14 Jan 2008 Status change from recruiting to in progress.
- 16 Feb 2007 New trial record.